体外诊断是指将血液、体液、组织等样本从人体中取出，使用体外检测试剂、 仪器等对样本进行检测与校验，以便对疾病进行预防、诊断、治疗检测、后 期观察、健康评价、遗传疾病预测。体外诊断产品主要由诊断设备（仪器） 和诊断试剂构成，根据检测原理方法以及检测环境条件可以分成包括生化诊 断、免疫诊断、分子诊断、现场即时检测（POCT）等主要领域。

Sexual Lubricants, also known as lubes or personal lubricants, are a kind of gel, cream, fluid, or liquid that are used to reduce friction between the vagina & penis during sexual intercourse and reduces pain. Lubes are used to enhance the sexual experience and get more pleasure. Using sexual lubricants while sexual intercourse may be helpful for women experiencing vaginal dryness, & men who have erectile dysfunction. These are used widely for men, women, transgender, and LGBTQ+ community globally. They are used with condoms as well for additional comfort & ease and sometimes to reduce condom breakage. These lubricants are applied to the condom, penis, vagina, or rectum during sexual activity as it improves moistening. They are generally preferred by sex workers and men who have sex with men (MSM).

Sexual health supplements help improve potency during sexual activities, erectile dysfunction, infertility, and other conditions. They are consumed orally. Sexual health supplements are available in the market without a prescription and usually do not have any side effects on the human body. They are available in capsules, tablets, soft gels, liquids, and powders. Nutritional supplements are a part of the daily diet globally due to aging, lifestyle changes, and other factors. Common supplements include minerals, vitamins, and herbal products.

Self/home-based pregnancy test kits were the first rapid test kits under point-of-care (POC) diagnostics developed in 1976. The pregnancy test kit was developed in 1976. Pregnancy test kits are medical devices used to detect signs of pregnancy among women. The Human Chorionic Gonadotropin (hCG) hormone is considered a standard gold biomarker that provides overall information about pregnancy to identify the pregnancy. This hormone develops in the placenta during pregnancy. It helps to thicken the uterine lining, which supports to growth embryo and sends the signal to the body to stop menstruation. The level of hCG increase after conception and continue to increase until around ten weeks into pregnancy.

Infection control surveillance solutions are an integral component of healthcare systems that are designed to help prevent and control HAIs. These solutions range from comprehensive infection control systems that incorporate surveillance of pathogens, antimicrobial therapy management, infection prevention strategies, and antibiotic stewardship programs to more focused solutions that help track and monitor nosocomial and antimicrobial resistance (AMR) in a hospital setting. By recognizing the scope and prevalence of HAIs, infection control surveillance solutions help health professionals identify areas of potential concern and reduce the impact of infectious outbreaks.

国内二类苗市场快速发展，重磅产品有望持续放量。近年来，全球疫苗市场呈现快速发展，驱动因素主要是由发达国家及发展中国家创新疫苗的普及、不断增长的医疗支出及疫苗接种意识的提高。新冠疫苗研发也推动了疫苗相关技术的进一步发展。国内疫苗市场也处于加速发展中，增速快于全球市场。且随着人均可支配收入提升，以及人群预防接种意识的觉醒和新品种诱发的接种需求，预计二类苗产品的市场规模将持续扩大。随着国产重磅疫苗产品陆续上市并实现国产替代，国内疫苗行业进入大品种时代，国内婴幼儿及成人重磅疫苗产品有望持续放量，渗透率提升空间较大。

诺和诺德司美格鲁肽在此前CVOT 临床试验成功的基础上又再下一城，在 慢性肾病FLOW III 期临床研究中因达到预期终点而提前终止临床试验，相 应用药人群全球超1 亿人，市场空间超200 亿美元。我们认为，GLP-1 类 药物目前已在2 型糖尿病、超重与肥胖、心脑血管疾病、射血分数保留型 心衰和慢性肾病中展现出临床获益，可覆盖人群庞大。未来，GLP-1 类药 物有望在NASH 和AD 等适应症中迎来突破，造福更多患者的同时进一步 提升靶点及产业价值。

9 月上证综指下跌0.3%，SW 医药生物指数上涨4.3%，涨跌幅在28 个申万一级 行业中排名第1 名。生物医药板块中表现相对较好的细分板块是化学制剂 （8.3%）、化学原料药（5.0%）、生物制品（4.7%）。个股涨幅前三为常山药业 （+181.09%）、通化金马（+87.78%）、博瑞医药（+58.50%）；个股跌幅前三为民 生健康（-33.13%）、易瑞生物（-16.30%）、科源制药（-14.13%）（剔除上市1 个 月内个股、ST 个股）。截至2023 年9 月底，医药板块PE（TTM）为26.32 倍（剔 除负值），相对于全部A 股的溢价率89.99%。

全球心衰患病率近年呈增长趋势，左心室辅助装置（LVAD）为晚期心衰的主要治疗手段。无论是中国还是全球，心衰患病率 近年均呈增长趋势，根据CHS（2012-2015）的一项统计，中国年龄≥35岁的心衰患者约为890万人。每年25岁及以上心衰 新发患者约为297万；全球心衰患者约为6400万人。从美国治疗晚期心力衰竭（Advanced heart failure）的指南推荐来看， 晚期心衰主要治疗方法包括心脏移植、左心室辅助装置（或耐用机械循环支持设备）和姑息治疗三种。心脏移植存在等待时 间长的问题，长期机械循环支持设备（MCS）有望成为晚期心衰的主要治疗手段（2a级（美国）/1级（欧洲），仅次于心脏 移植）。其中左心室辅助装置（LVAD）作为耐用MCS的一种，由于其优异的性能，在使用方面占据全球主导地位，作为移植 前过渡或终极治疗。

市场行情回顾。9 月（2023 年9 月1 日至9 月30 日），中信生物 医药行业指数上涨4.23%（按照流通市值加权平均计算），同期 沪深300 下跌0.97%，（按照流通市值加权平均计算），跑赢沪深 300 5.2 个百分点，行业整体表现在30 个中信二级行业指数中排 名第3 位，较上月排名快速上升。